Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while First Trust NASDAQ Cybersecurity ETF trades at $92.26. The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CIBR | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $94.32 |
52-Week Low | $278.09 | $60.74 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CIBR trades at $91.88, down 2.52% today but maintains strong bullish momentum with 17 buy signals versus 5 sell signals. The cybersecurity ETF has significantly outperformed the S&P 500, delivering 22% returns since December 2025 compared to the index's 8%. Recent technical indicators show overbought conditions with RSI above 80, while moving averages remain strongly bullish. The fund benefits from growing cybersecurity spending exceeding $300 billion in 2026 and captures exposure to 30+ cybersecurity companies including CrowdStrike.
The outlook remains positive given structural growth in cybersecurity demand, though current overbought conditions suggest potential near-term consolidation. Key risks include concentrated tech exposure and valuation sensitivity. Institutional ownership continues to grow with recent filings showing significant position increases by wealth management firms, supporting the long-term investment case for digital defense exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
